Natera stock jumps over 20% to record high after stellar Q2 results

Natera’s stock closed at $322.10 on Friday, a 21.3% increase that set a new record price for the company. The jump followed the release of a second-quarter earnings release showing revenue of $752.8 million, surpassing analysts’ expectations of $673.9 million and prompting a market-cap rise to $46.1 billion from around $38 billion a month earlier. The strong performance was driven by a surge in volume for the Signatera cancer-detecting blood test, which analysts described as “blowout volume.”

Co-founder Matthew Rabinowitz’s estimated wealth climbed to at least $1.5 billion, reflecting his ownership of roughly 2.28 million shares and additional options and RSUs. The stock has appreciated about 40.6% since the beginning of the year, after hitting a low of $182.65 in late March. Rabinowitz also holds about 19.4% of genome-focused firm MyOme on a fully diluted basis. His background includes leading a location-services company, serving as Natera’s CEO for 14 years, and receiving awards for work in bioinformatics and genetics.